{"pmid":32463179,"title":"Exposure to DPP-4 inhibitors and COVID-19 among people with type 2 diabetes. A case-control study.","text":["Exposure to DPP-4 inhibitors and COVID-19 among people with type 2 diabetes. A case-control study.","Because other coronaviruses enter the cells by binding to dipeptidyl-peptidase-4 (DPP-4), it has been speculated that DPP-4 inhibitors (DPP-4i) may exert an activity against SARS-CoV-2. In the absence of clinical trial results, we analyzed epidemiological data to support or discard such hypothesis. We retrieved information on exposure to DPP-4i among patients with type 2 diabetes (T2D) hospitalized for COVID-19 at an outbreak hospital in Italy. As reference, we retrieved exposure to DPP-4i among matched T2D patients in the same Region. Of 403 hospitalized COVID-19 patients, 85 had T2D. The rate of exposure to DPP-4i was similar between T2D patients with COVID-19 (10.6%) and 14 857 matched patients in the Region (8.8%), or 793 matched patients in the local outpatient clinic (15.4%), 8284 matched patients hospitalized for other reasons (8.5%), and when comparing 71 patients hospitalized for COVID-19 pneumonia (11.3%) to 351 matched patients with pneumonia of other etiology (10.3%). T2D patients with COVID-19 who were on DPP-4i had a similar disease outcome as those who were not. In summary, we found no evidence that DPP-4i might affect hospitalization for COVID-19. This article is protected by copyright. All rights reserved.","Diabetes Obes Metab","Fadini, Gian Paolo","Morieri, Mario Luca","Longato, Enrico","Bonora, Benedetta Maria","Pinelli, Silvia","Selmin, Elisa","Voltan, Giacomo","Falaguasta, Daniele","Tresso, Silvia","Costantini, Giorgia","Sparacino, Giovanni","Di Camillo, Barbara","Tramontan, Lara","Cattelan, Anna Maria","Vianello, Andrea","Fioretto, Paola","Vettor, Roberto","Avogaro, Angelo","32463179"],"abstract":["Because other coronaviruses enter the cells by binding to dipeptidyl-peptidase-4 (DPP-4), it has been speculated that DPP-4 inhibitors (DPP-4i) may exert an activity against SARS-CoV-2. In the absence of clinical trial results, we analyzed epidemiological data to support or discard such hypothesis. We retrieved information on exposure to DPP-4i among patients with type 2 diabetes (T2D) hospitalized for COVID-19 at an outbreak hospital in Italy. As reference, we retrieved exposure to DPP-4i among matched T2D patients in the same Region. Of 403 hospitalized COVID-19 patients, 85 had T2D. The rate of exposure to DPP-4i was similar between T2D patients with COVID-19 (10.6%) and 14 857 matched patients in the Region (8.8%), or 793 matched patients in the local outpatient clinic (15.4%), 8284 matched patients hospitalized for other reasons (8.5%), and when comparing 71 patients hospitalized for COVID-19 pneumonia (11.3%) to 351 matched patients with pneumonia of other etiology (10.3%). T2D patients with COVID-19 who were on DPP-4i had a similar disease outcome as those who were not. In summary, we found no evidence that DPP-4i might affect hospitalization for COVID-19. This article is protected by copyright. All rights reserved."],"journal":"Diabetes Obes Metab","authors":["Fadini, Gian Paolo","Morieri, Mario Luca","Longato, Enrico","Bonora, Benedetta Maria","Pinelli, Silvia","Selmin, Elisa","Voltan, Giacomo","Falaguasta, Daniele","Tresso, Silvia","Costantini, Giorgia","Sparacino, Giovanni","Di Camillo, Barbara","Tramontan, Lara","Cattelan, Anna Maria","Vianello, Andrea","Fioretto, Paola","Vettor, Roberto","Avogaro, Angelo"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32463179","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/dom.14097","locations":["Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Treatment"],"weight":1,"_version_":1668079521354481664,"score":9.490897,"similar":[{"pmid":32294179,"pmcid":"PMC7184382","title":"Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications.","text":["Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications.","Individuals with diabetes are at increased risk for bacterial, mycotic, parasitic, and viral infections. The severe acute respiratory syndrome (SARS)-CoV-2 (also referred to as COVID-19) coronavirus pandemic highlights the importance of understanding shared disease pathophysiology potentially informing therapeutic choices in individuals with type 2 diabetes (T2D). Two coronavirus receptor proteins, angiotensin-converting enzyme 2 (ACE2) and dipeptidyl peptidase-4 (DPP4) are also established transducers of metabolic signals and pathways regulating inflammation, renal and cardiovascular physiology, and glucose homeostasis. Moreover, glucose-lowering agents such as the DPP4 inhibitors, widely used in subjects with T2D, are known to modify the biological activities of multiple immunomodulatory substrates. Here, we review the basic and clinical science spanning the intersections of diabetes, coronavirus infections, ACE2, and DPP4 biology, highlighting clinical relevance and evolving areas of uncertainty underlying the pathophysiology and treatment of T2D in the context of coronavirus infection.","Endocr Rev","Drucker, Daniel J","32294179"],"abstract":["Individuals with diabetes are at increased risk for bacterial, mycotic, parasitic, and viral infections. The severe acute respiratory syndrome (SARS)-CoV-2 (also referred to as COVID-19) coronavirus pandemic highlights the importance of understanding shared disease pathophysiology potentially informing therapeutic choices in individuals with type 2 diabetes (T2D). Two coronavirus receptor proteins, angiotensin-converting enzyme 2 (ACE2) and dipeptidyl peptidase-4 (DPP4) are also established transducers of metabolic signals and pathways regulating inflammation, renal and cardiovascular physiology, and glucose homeostasis. Moreover, glucose-lowering agents such as the DPP4 inhibitors, widely used in subjects with T2D, are known to modify the biological activities of multiple immunomodulatory substrates. Here, we review the basic and clinical science spanning the intersections of diabetes, coronavirus infections, ACE2, and DPP4 biology, highlighting clinical relevance and evolving areas of uncertainty underlying the pathophysiology and treatment of T2D in the context of coronavirus infection."],"journal":"Endocr Rev","authors":["Drucker, Daniel J"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294179","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1210/endrev/bnaa011","keywords":["angiotensin converting enzyme 2","diabetes","dipeptidyl peptidase-4","obesity","receptor","virus"],"e_drugs":["Glucose"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494448173057,"score":476.1448},{"pmid":32416120,"title":"Is DPP4 inhibition a comrade or adversary in COVID-19 Infection.","text":["Is DPP4 inhibition a comrade or adversary in COVID-19 Infection.","Hypertension and Diabetes are the most common comorbid conditions in patients with COVID-19 and has been shown to adversely impact prognosis globally. It has been shown that hyperglycemia is one of the factors that increases the risk of poor outcomes in these patients . These patients are usually on multiple medications and recently a series of discussion on how Dipeptidyl peptidase 4 inhibitors (DPP4i) may be beneficial in these patients has been presented. This commentary presents a nuanced debateon why the DPP4i may not bebeneficial in COVID-19 and that caution needs to be addressed in making any judgementsuntil real world data is available.","Diabetes Res Clin Pract","Dalan, Rinkoo","32416120"],"abstract":["Hypertension and Diabetes are the most common comorbid conditions in patients with COVID-19 and has been shown to adversely impact prognosis globally. It has been shown that hyperglycemia is one of the factors that increases the risk of poor outcomes in these patients . These patients are usually on multiple medications and recently a series of discussion on how Dipeptidyl peptidase 4 inhibitors (DPP4i) may be beneficial in these patients has been presented. This commentary presents a nuanced debateon why the DPP4i may not bebeneficial in COVID-19 and that caution needs to be addressed in making any judgementsuntil real world data is available."],"journal":"Diabetes Res Clin Pract","authors":["Dalan, Rinkoo"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32416120","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.diabres.2020.108216","keywords":["covid-19","dpp-4 inhibitors"],"topics":["Treatment"],"weight":1,"_version_":1666994545855823872,"score":382.92902},{"pmid":32369736,"title":"Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes.","text":["Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes.","Type 2 diabetes (T2D) is a major comorbidity of COVID-19. However, the impact of blood glucose (BG) control on the degree of required medical interventions and on mortality in patients with COVID-19 and T2D remains uncertain. Thus, we performed a retrospective, multi-centered study of 7,337 cases of COVID-19 in Hubei Province, China, among which 952 had pre-existing T2D. We found that subjects with T2D required more medical interventions and had a significantly higher mortality (7.8% versus 2.7%; adjusted hazard ratio [HR], 1.49) and multiple organ injury than the non-diabetic individuals. Further, we found that well-controlled BG (glycemic variability within 3.9 to 10.0 mmol/L) was associated with markedly lower mortality compared to individuals with poorly controlled BG (upper limit of glycemic variability exceeding 10.0 mmol/L) (adjusted HR, 0.14) during hospitalization. These findings provide clinical evidence correlating improved glycemic control with better outcomes in patients with COVID-19 and pre-existing T2D.","Cell Metab","Zhu, Lihua","She, Zhi-Gang","Cheng, Xu","Qin, Juan-Juan","Zhang, Xiao-Jing","Cai, Jingjing","Lei, Fang","Wang, Haitao","Xie, Jing","Wang, Wenxin","Li, Haomiao","Zhang, Peng","Song, Xiaohui","Chen, Xi","Xiang, Mei","Zhang, Chaozheng","Bai, Liangjie","Xiang, Da","Chen, Ming-Ming","Liu, Yanqiong","Yan, Youqin","Liu, Mingyu","Mao, Weiming","Zou, Jinjing","Liu, Liming","Chen, Guohua","Luo, Pengcheng","Xiao, Bing","Zhang, Changjiang","Zhang, Zixiong","Lu, Zhigang","Wang, Junhai","Lu, Haofeng","Xia, Xigang","Wang, Daihong","Liao, Xiaofeng","Peng, Gang","Ye, Ping","Yang, Jun","Yuan, Yufeng","Huang, Xiaodong","Guo, Jiao","Zhang, Bing-Hong","Li, Hongliang","32369736"],"abstract":["Type 2 diabetes (T2D) is a major comorbidity of COVID-19. However, the impact of blood glucose (BG) control on the degree of required medical interventions and on mortality in patients with COVID-19 and T2D remains uncertain. Thus, we performed a retrospective, multi-centered study of 7,337 cases of COVID-19 in Hubei Province, China, among which 952 had pre-existing T2D. We found that subjects with T2D required more medical interventions and had a significantly higher mortality (7.8% versus 2.7%; adjusted hazard ratio [HR], 1.49) and multiple organ injury than the non-diabetic individuals. Further, we found that well-controlled BG (glycemic variability within 3.9 to 10.0 mmol/L) was associated with markedly lower mortality compared to individuals with poorly controlled BG (upper limit of glycemic variability exceeding 10.0 mmol/L) (adjusted HR, 0.14) during hospitalization. These findings provide clinical evidence correlating improved glycemic control with better outcomes in patients with COVID-19 and pre-existing T2D."],"journal":"Cell Metab","authors":["Zhu, Lihua","She, Zhi-Gang","Cheng, Xu","Qin, Juan-Juan","Zhang, Xiao-Jing","Cai, Jingjing","Lei, Fang","Wang, Haitao","Xie, Jing","Wang, Wenxin","Li, Haomiao","Zhang, Peng","Song, Xiaohui","Chen, Xi","Xiang, Mei","Zhang, Chaozheng","Bai, Liangjie","Xiang, Da","Chen, Ming-Ming","Liu, Yanqiong","Yan, Youqin","Liu, Mingyu","Mao, Weiming","Zou, Jinjing","Liu, Liming","Chen, Guohua","Luo, Pengcheng","Xiao, Bing","Zhang, Changjiang","Zhang, Zixiong","Lu, Zhigang","Wang, Junhai","Lu, Haofeng","Xia, Xigang","Wang, Daihong","Liao, Xiaofeng","Peng, Gang","Ye, Ping","Yang, Jun","Yuan, Yufeng","Huang, Xiaodong","Guo, Jiao","Zhang, Bing-Hong","Li, Hongliang"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32369736","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.cmet.2020.04.021","keywords":["covid-19","sars-cov-2","blood glucose control","diabetes mellitus","mortality"],"locations":["Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Glucose","Blood Glucose"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138496280035328,"score":370.0345},{"pmid":32336007,"title":"DPP4 inhibition: preventing SARS-CoV-2 infection and/or progression of COVID-19?","text":["DPP4 inhibition: preventing SARS-CoV-2 infection and/or progression of COVID-19?","Dipeptidyl peptidase 4 (DPP4), also known as cluster of differentiation 26 (CD26), is a serine exopeptidase expressed ubiquitously in several tissues, including but not limited to lung, kidney, liver, gut, and immune cells. The question has been raised on whether DPP4 modulation or inhibition may prevent infection and/or progression of the COVID-19. A docked complex model of the SARS-CoV-2 spike glycoprotein and DPP4 has been proposed, showing a large interface between the proteins and proposing close similarity with other coronaviruses using DPP4 as functional receptor. In absence of experimental validation, these data should be interpreted with caution. Nevertheless, this observation may rise the question on whether DPP4 is directly involved in SARS-CoV-2 cell adhesion/virulence, and whether DPP4 inhibition might be a therapeutic strategy for preventing infection. Although a direct involvement of DPP4 in SARS-CoV-2 infection needs to be clarified, there is also evidence suggesting that DPP4i modulate inflammation and exert anti-fibrotic activity. These properties may be of potential use for halting progression to the hyperinflammatory state associated with severe COVID-19. Taken together these findings may suggest a potential role for DPP4 inhibition or modulation in one or more steps of COVID-19 immunopathogenesis. This article is protected by copyright. All rights reserved.","Diabetes Metab Res Rev","Strollo, Rocky","Pozzilli, Paolo","32336007"],"abstract":["Dipeptidyl peptidase 4 (DPP4), also known as cluster of differentiation 26 (CD26), is a serine exopeptidase expressed ubiquitously in several tissues, including but not limited to lung, kidney, liver, gut, and immune cells. The question has been raised on whether DPP4 modulation or inhibition may prevent infection and/or progression of the COVID-19. A docked complex model of the SARS-CoV-2 spike glycoprotein and DPP4 has been proposed, showing a large interface between the proteins and proposing close similarity with other coronaviruses using DPP4 as functional receptor. In absence of experimental validation, these data should be interpreted with caution. Nevertheless, this observation may rise the question on whether DPP4 is directly involved in SARS-CoV-2 cell adhesion/virulence, and whether DPP4 inhibition might be a therapeutic strategy for preventing infection. Although a direct involvement of DPP4 in SARS-CoV-2 infection needs to be clarified, there is also evidence suggesting that DPP4i modulate inflammation and exert anti-fibrotic activity. These properties may be of potential use for halting progression to the hyperinflammatory state associated with severe COVID-19. Taken together these findings may suggest a potential role for DPP4 inhibition or modulation in one or more steps of COVID-19 immunopathogenesis. This article is protected by copyright. All rights reserved."],"journal":"Diabetes Metab Res Rev","authors":["Strollo, Rocky","Pozzilli, Paolo"],"date":"2020-04-27T11:00:00Z","year":2020,"_id":"32336007","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/dmrr.3330","keywords":["cd26","covid-19","dpp4 inhibitors","dipeptidyl peptidase 4","sars-cov-2","coronavirus"],"e_drugs":["Serine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494096900096,"score":366.22388},{"pmid":32394639,"title":"Covid-19 and co-morbidities: a role for Dipeptidyl Peptidase 4 (DPP4) in disease severity?","text":["Covid-19 and co-morbidities: a role for Dipeptidyl Peptidase 4 (DPP4) in disease severity?","The Covid-19 pandemic is caused by a novel betacoronavirus, SARS-CoV-2, similar to SARS-CoV and MERS-CoV, which cause acute respiratory distress syndrome and case fatalities. Covid-19 disease severity is worse in older obese patients with comorbidities such as diabetes, hypertension, cardiovascular disease and chronic lung disease. Cell binding and entry of betacoronaviruses is via their surface spike glycoprotein; SARS-CoV binds to the metalloprotease angiotensin-converting enzyme 2, abbreviated hereafter to ACE2, MERS-CoV utilises dipeptidyl peptidase 4, abbreviated hereafter to DPP4, and recent modelling of the structure of SARS-CoV-2 spike glycoprotein predicts that it can interact with human DPP4 in addition to ACE2. DPP4 is a ubiquitous membrane-bound aminopeptidase that circulates in plasma; it is multifunctional with roles in nutrition, metabolism, immune and endocrine systems. DPP4 activity differentially regulates glucose homeostasis and inflammation via its enzymatic activity and non-enzymatic immunomodulatory effects. The importance of DPP4 for the medical community has been highlighted by the approval of DPP4 inhibitors, or gliptins, for the treatment of Type 2 diabetes mellitus. This review discusses the dysregulation of DPP4 in Covid-19 comorbid conditions; DPP4 activity is higher in older individuals and increased plasma DPP4 is a predictor of the onset of metabolic syndrome. DPP4 upregulation may be a determinant of Covid-19 disease severity, which creates interest regarding the use of gliptins in management of Covid-19. Also, knowledge of the chemistry and biology of DPP4 could be utilised to develop novel therapies to block viral entry of some betacoronaviruses, potentially including SARS-CoV-2. This article is protected by copyright. All rights reserved.","J Diabetes","Bassendine, Margaret F","Bridge, Simon H","McCaughan, Geoffrey W","Gorrell, Mark D","32394639"],"abstract":["The Covid-19 pandemic is caused by a novel betacoronavirus, SARS-CoV-2, similar to SARS-CoV and MERS-CoV, which cause acute respiratory distress syndrome and case fatalities. Covid-19 disease severity is worse in older obese patients with comorbidities such as diabetes, hypertension, cardiovascular disease and chronic lung disease. Cell binding and entry of betacoronaviruses is via their surface spike glycoprotein; SARS-CoV binds to the metalloprotease angiotensin-converting enzyme 2, abbreviated hereafter to ACE2, MERS-CoV utilises dipeptidyl peptidase 4, abbreviated hereafter to DPP4, and recent modelling of the structure of SARS-CoV-2 spike glycoprotein predicts that it can interact with human DPP4 in addition to ACE2. DPP4 is a ubiquitous membrane-bound aminopeptidase that circulates in plasma; it is multifunctional with roles in nutrition, metabolism, immune and endocrine systems. DPP4 activity differentially regulates glucose homeostasis and inflammation via its enzymatic activity and non-enzymatic immunomodulatory effects. The importance of DPP4 for the medical community has been highlighted by the approval of DPP4 inhibitors, or gliptins, for the treatment of Type 2 diabetes mellitus. This review discusses the dysregulation of DPP4 in Covid-19 comorbid conditions; DPP4 activity is higher in older individuals and increased plasma DPP4 is a predictor of the onset of metabolic syndrome. DPP4 upregulation may be a determinant of Covid-19 disease severity, which creates interest regarding the use of gliptins in management of Covid-19. Also, knowledge of the chemistry and biology of DPP4 could be utilised to develop novel therapies to block viral entry of some betacoronaviruses, potentially including SARS-CoV-2. This article is protected by copyright. All rights reserved."],"journal":"J Diabetes","authors":["Bassendine, Margaret F","Bridge, Simon H","McCaughan, Geoffrey W","Gorrell, Mark D"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32394639","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/1753-0407.13052","keywords":["case fatality","covid-19","dipeptidyl-peptidase iv inhibitors","metabolic syndrome","sars-cov-2"],"locations":["obese"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666627827907166208,"score":197.29343}]}